# Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

> **NCT03763370** · — · AVAILABLE · sponsor: **GlaxoSmithKline**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)
- **DRUG:** Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)

## Key facts

- **NCT ID:** NCT03763370
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763370, "Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03763370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*